Barbara Pro

17.2k total citations · 5 hit papers
289 papers, 9.9k citations indexed

About

Barbara Pro is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Barbara Pro has authored 289 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Pathology and Forensic Medicine, 137 papers in Oncology and 85 papers in Genetics. Recurrent topics in Barbara Pro's work include Lymphoma Diagnosis and Treatment (234 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Viral-associated cancers and disorders (54 papers). Barbara Pro is often cited by papers focused on Lymphoma Diagnosis and Treatment (234 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Viral-associated cancers and disorders (54 papers). Barbara Pro collaborates with scholars based in United States, France and Italy. Barbara Pro's co-authors include Peter McLaughlin, Luis Fayad, Anas Younes, Jorge Romaguera, Andrei R. Shustov, Felipe Samaniego, Maria Alma Rodriguez, André Goy, Nam H. Dang and Fernando Cabanillas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Barbara Pro

282 papers receiving 9.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

2012 711 citations Barbara Pro, Ranjana H. Advani et al. Journal of Clinical Oncology profile →
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

2009 506 citations Massimo Federico, Monica Bellei et al. Journal of Clinical Oncology profile →
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

2013 384 citations Luis Fayad, Barbara Pro et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Barbara Pro

Since Specialization

Citations

This map shows the geographic impact of Barbara Pro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Pro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Pro more than expected).

Fields of papers citing papers by Barbara Pro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Pro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Pro. The network helps show where Barbara Pro may publish in the future.

Co-authorship network of co-authors of Barbara Pro

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Pro. A scholar is included among the top collaborators of Barbara Pro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Pro. Barbara Pro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas 2025 ·Blood ·Seda S. Tolu, (unknown), Manuel Pazos, (unknown), Aleksandar Obradović, (unknown), Barbara Pro, Jennifer E. Amengual	0
2	Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial 2024 ·Blood ·(unknown), Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren Pinter‐Brown, Koji Izutsu, Ohad S. Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Sarah McCue Horwitz	4
3	Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma 2024 ·Blood ·Jennifer E. Amengual, Aung M. Tun, (unknown), (unknown), Victor Yazbeck, (unknown), Seda S. Tolu, Barbara Pro, Diane E. Durecki, Jan H. Beumer, Neil L. Kelleher, (unknown), (unknown), (unknown), (unknown), Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz	2
4	Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma 2023 ·Blood Advances ·Jia Ruan, Jasmine M. Zain, (unknown), Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane N. Winter, Leo I. Gordon, Reem Karmali, Jonathan Moreira, Adam M. Petrich, Barbara Pro	19
5	Identifying and addressing unmet clinical needs in primary cutaneous B‐cell lymphoma: A consensus‐based paper from an ad‐hoc international panel 2023 ·Hematological Oncology ·Pietro Quaglino, Nicola Pimpinelli, Pier Luigi Zinzani, Marco Paulli, Stefano Pileri, Emilio Berti, Lorenzo Cerroni, Joan Guitart, Youn H. Kim, Serena Rupoli, Marco Santucci, Gabriele Simontacchi, Maarten H. Vermeer, Richard T. Hoppe, Barbara Pro, Steven H. Swerdlow, Giovanni Barosi	1
6	Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Frederick Lansigan, Sarah McCue Horwitz, Lauren Pinter‐Brown, Kenneth R. Carson, Andrei R. Shustov, Steven T. Rosen, Barbara Pro, Eric D. Hsi, Massimo Federico, Christian Gisselbrecht, Marc Schwartz, Lisa A. Bellm, Mark Acosta, Francine M. Foss	9
7	Radiation Oncology Education for Medical Oncology Fellowship Trainees: A Pilot Needs Assessment 2018 ·International Journal of Radiation OncologyBiologyPhysics ·N Paudel, Barbara Pro, (unknown), Wade T. Iams, Daniel W. Golden, Tim J. Kruser	1
8	Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas 2017 ·Blood ·Michelle A. Fanale, Sarah McCue Horwitz, Andres Forero‐Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, (unknown), Dirk Huebner, Hong Ren, Andrei R. Shustov	3
9	Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data 2016 ·Blood ·Pier Luigi Zinzani, Max S. Topp, Sam Yuen, Chiara Rusconi, Isabelle Fleury, Barbara Pro, Giuseppe Gritti, Michael Crump, (unknown), Elizabeth A. Punnoose, James Hilger, Mehrdad Mobasher, (unknown)	23
10	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial 2015 ·British Journal of Haematology ·Ranjana H. Advani, Stephen M. Ansell, Mary Jo Lechowicz, Anne Beaven, Fausto R. Loberiza, Kenneth R. Carson, Andrew M. Evens, Francine M. Foss, Steven M. Horwitz, Barbara Pro, Lauren Pinter‐Brown, Sonali M. Smith, Andrei R. Shustov, Kerry J. Savage, Julie M. Vose	66
11	Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma 2015 ·Annals of Oncology ·Sarah McCue Horwitz, Bertrand Coiffier, Francine M. Foss, H. Miles Prince, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Franck Morschhauser, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, (unknown), John Balser, Barbara Balser, Barbara Pro	12
12	Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ^® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas 2013 ·British Journal of Haematology ·Fredrick B. Hagemeister, Maria Alma Rodriguez, Steven R. Deitcher, Anas Younes, Luis Fayad, André Goy, Nam H. Dang, Arthur Forman, Peter McLaughlin, Leonard Jeffrey Medeiros, Barbara Pro, Jorge Romaguera, Felipe Samaniego, Jeffrey A. Silverman, Andreas H. Sarris, Fernando Cabanillas	24
13	Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy breakdown → 2012 ·Journal of Clinical Oncology ·Bertrand Coiffier, Barbara Pro, H. Miles Prince, Francine M. Foss, Lubomir Sokol, Matthew Greenwood, Dolores Caballero, Peter Borchmann, Franck Morschhauser, Martin Wilhelm, Lauren Pinter‐Brown, Swaminathan P. Iyer, Andrei R. Shustov, Jean Nichols, Susan Carroll, John Balser, Barbara Balser, Sarah McCue Horwitz	485
14	Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database 2012 ·Journal of Clinical Oncology ·Philippe Solal‐Céligny, Monica Bellei, Luigi Marcheselli, Emanuela Anna Pesce, Stefano Pileri, Peter McLaughlin, Stefano Luminari, Barbara Pro, Silvia Montoto, Andrés J.M. Ferreri, Éric Deconinck, Nöel Milpied, Leo I. Gordon, Massimo Federico	88
15	Brentuximab vedotin in Hodgkin's lymphoma 2012 ·Expert Opinion on Biological Therapy ·Barbara Pro, Guilherme Fleury Perini	14
16	Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study breakdown → 2011 ·Journal of Clinical Oncology ·Owen A. O’Connor, Barbara Pro, Lauren Pinter‐Brown, Nancy L. Bartlett, Leslie Popplewell, Bertrand Coiffier, Mary Jo Lechowicz, Kerry J. Savage, Andrei R. Shustov, Christian Gisselbrecht, Eric D. Jacobsen, Pier Luigi Zinzani, Richard R. Furman, André Goy, Corinne Haïoun, Michael Crump, Jasmine Zain, Eric D. Hsi, Adam P. Boyd, Steven M. Horwitz	439
17	Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma 2009 ·Journal of Clinical Oncology ·Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Romaguera, Maria Alma Rodriguez, Felipe Samaniego, Peter McLaughlin, Frederick Hagemeister, Sattva S. Neelapu, Amanda Copeland, Barry I. Samuels, Evelyne M. Loyer, Yuan Ji, Anas Younes	66
18	Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group 2007 ·Haematologica ·David Christie, Elías Gracia, M. Gospodarowicz, G Martinelli, Katherine J. Deans, (unknown), (unknown), (unknown), Dae Seog Heo, David Porter, John Radford, H.H. Lucraft, (unknown), Nick Pavlakis, (unknown), (unknown), Carlo Visco, Barbara Pro	3
19	The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma 2007 ·Annals of Oncology ·Michael J. Overman, Lei Feng, Barbara Pro, Peter McLaughlin, (unknown), Felipe Samaniego, Anas Younes, Jorge Romaguera, Frederick Hagemeister, Larry W. Kwak, Fernando Cabanillas, Maria Alma Rodriguez, Luis Fayad	16
20	Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60. 2004 ·Cancer Research ·(unknown), Maria Alma Rodriguez, Fernando Cabanillas, Nam H. Dang, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Anas Younes, Elizabeth A. Grimm	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact